UHS Stock Analysis: Universal Health | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 9.585m USD | 12M Return: -13.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 139M
EPS Trend: 98.9%
Qual. Beats: 0
Rev. Trend: 99.9%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Universal Health Services, Inc. (UHS) is a U.S.-based, for-profit hospital operator headquartered in King of Prussia, Pennsylvania, founded in 1978. The company runs a dual-segment model consisting of Acute Care Hospital Services and Behavioral Health Care Services, operating a network of acute care hospitals alongside outpatient and behavioral health facilities across the United States.
In addition to direct patient care - including general and specialty surgery, emergency services, oncology, diagnostic care, obstetrics, and pediatrics - UHS offers commercial health insurance products and shared management services such as purchasing, IT, finance, facilities planning, physician recruitment, and marketing to its facilities. The behavioral health segment, in particular, has been a defining feature of UHSs portfolio, as the company is one of the largest operators of inpatient behavioral health facilities in the U.S., a niche that tends to face less reimbursement pressure than acute care. Acute care hospitals, by contrast, operate in a sector characterized by high fixed costs, reliance on Medicare/Medicaid reimbursement, and ongoing labor expense pressure. UHS has been publicly traded on the NYSE since 1990.
- Behavioral health same-facility volume drives higher-margin revenue growth
- Acute care margins squeezed by persistent nursing labor cost inflation
- Medicaid supplemental payment programs and reimbursement rates impact profitability
| Net Income: 1.52b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -1.40 > 1.0 |
| NWC/Revenue: 1.44% < 20% (prev 4.65%; Δ -3.21% < -1%) |
| CFO/TA 0.12 > 3% & CFO 1.91b > Net Income 1.52b |
| Net Debt (5.42b) to EBITDA (2.80b): 1.94 < 3 |
| Current Ratio: 1.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (61.7m) vs 12m ago -6.55% < -2% |
| Gross Margin: 71.32% > 18% (prev 90.13%; Δ -18.81% > 0.5%) |
| Asset Turnover: 116.2% > 50% (prev 108.1%; Δ 8.12% > 0%) |
| Interest Coverage Ratio: 14.45 > 6 (EBIT TTM 2.17b / Interest Expense TTM 150.3m) |
| A: 0.02 (Total Current Assets 3.50b - Total Current Liabilities 3.24b) / Total Assets 15.7b |
| B: 0.52 (Retained Earnings 8.20b / Total Assets 15.7b) |
| C: 0.14 (EBIT TTM 2.17b / Avg Total Assets 15.3b) |
| D: 0.93 (Book Value of Equity 7.53b / Total Liabilities 8.11b) |
| Altman-Z'' = 3.74 = AA |
| DSRI: 1.03 (Receivables 2.75b/2.41b, Revenue 17.8b/16.1b) |
| GMI: 1.26 (GM 90.13% / 71.32%) |
| AQI: -0.36 (AQ_t -0.12 / AQ_t-1 0.32) |
| SGI: 1.10 (Revenue 17.8b / 16.1b) |
| TATA: -0.02 (NI 1.52b - CFO 1.91b) / TA 15.7b) |
| Beneish M = -3.50 (Cap -4..+1) = AA |
As of July 05, 2026, the stock is trading at USD 158.33 with a total of 1,311,100 shares traded. Over the past week, the price has changed by +9.60%, over one month by +8.61%, over three months by -12.56% and over the past year by -13.83%.
Current recommended Stop Loss: 153.10 (which is 3.3% or 1.3 ATR below the current price).
Universal Health has received a consensus analysts rating of 3.68. Therefore, it is recommended to hold UHS.
- StrongBuy: 6
- Buy: 2
- Hold: 10
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 213.8 | 35% |
P/E Trailing = 6.6081
P/E Forward = 6.398
P/S = 0.5397
P/B = 1.2211
P/EG = 1.0489
Revenue TTM = 17.8b USD
EBIT TTM = 2.17b USD
EBITDA TTM = 2.80b USD
Long Term Debt = 3.95b USD (from longTermDebt, last quarter)
Short Term Debt = 829.1m USD (from shortTermDebt, last quarter)
Debt = 5.54b USD (from shortLongTermDebtTotal, last quarter) + Leases 417.5m
Net Debt = 5.42b USD (calculated: Debt 5.54b - CCE 119.0m)
Enterprise Value = 15.0b USD (9.58b + Debt 5.54b - CCE 119.0m)
Interest Coverage Ratio = 14.45 (Ebit TTM 2.17b / Interest Expense TTM 150.3m)
EV/FCF = 16.79x (Enterprise Value 15.0b / FCF TTM 894.0m)
FCF Yield = 5.96% (FCF TTM 894.0m / Enterprise Value 15.0b)
FCF Margin = 5.03% (FCF TTM 894.0m / Revenue TTM 17.8b)
Net Margin = 8.56% (Net Income TTM 1.52b / Revenue TTM 17.8b)
Gross Margin = 71.32% ((Revenue TTM 17.8b - Cost of Revenue TTM 5.09b) / Revenue TTM)
Gross Margin QoQ = 14.64% (prev 90.58%)
Tobins Q-Ratio = 0.96 (Enterprise Value 15.0b / Total Assets 15.7b)
Interest Expense / Debt = 2.71% (Interest Expense 150.3m / Debt 5.54b)
Taxrate = 23.39% (472.6m / 2.02b)
NOPAT = 1.66b (EBIT 2.17b * (1 - 23.39%))
Current Ratio = 1.08 (Total Current Assets 3.50b / Total Current Liabilities 3.24b)
Debt / Equity = 0.74 (Debt 5.54b / totalStockholderEquity, last quarter 7.53b)
Debt / EBITDA = 1.94 (Net Debt 5.42b / EBITDA 2.80b)
Debt / FCF = 6.07 (Net Debt 5.42b / FCF TTM 894.0m)
Total Stockholder Equity = 7.27b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.95% (Net Income 1.52b / Total Assets 15.7b)
RoE = 20.93% (Net Income TTM 1.52b / Total Stockholder Equity 7.27b)
RoCE = 19.35% (EBIT 2.17b / Capital Employed (Equity 7.27b + L.T.Debt 3.95b))
RoIC = 12.65% (NOPAT 1.66b / Invested Capital 13.1b)
WACC = 6.24% (E(9.58b)/V(15.1b) * Re(8.64%) + D(5.54b)/V(15.1b) * Rd(2.71%) * (1-Tc(0.23)))
Discount Rate = 8.64% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -94.39 | Cagr: -4.56%
[DCF] Terminal Value 73.10% ; FCFF base≈959.0m ; Y1≈841.0m ; Y5≈679.5m
[DCF] Fair Price = 102.9 (EV 10.9b - Net Debt 5.42b = Equity 5.48b / Shares 53.3m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 98.88 | EPS CAGR: 37.99% | SUE: 0.46 | # QB: 0
Revenue Correlation: 99.90 | Revenue CAGR: 9.86% | SUE: 1.72 | # QB: 1
EPS current Quarter (2026-06-30): EPS=5.98 | Chg30d=+1.50% | Revisions=-27% | Analysts=12
EPS next Quarter (2026-09-30): EPS=5.59 | Chg30d=-0.65% | Revisions=-40% | Analysts=12
EPS current Year (2026-12-31): EPS=23.43 | Chg30d=-0.02% | Revisions=-7% | GrowthEPS=+7.8% | GrowthRev=+6.7%
EPS next Year (2027-12-31): EPS=25.28 | Chg30d=-0.77% | Revisions=-21% | GrowthEPS=+7.9% | GrowthRev=+4.7%
[Analyst] Revisions Ratio: -29% (up=16, down=30)